BR112022012819A2 - Método para tratar mielofibrose em um paciente e kit - Google Patents

Método para tratar mielofibrose em um paciente e kit

Info

Publication number
BR112022012819A2
BR112022012819A2 BR112022012819A BR112022012819A BR112022012819A2 BR 112022012819 A2 BR112022012819 A2 BR 112022012819A2 BR 112022012819 A BR112022012819 A BR 112022012819A BR 112022012819 A BR112022012819 A BR 112022012819A BR 112022012819 A2 BR112022012819 A2 BR 112022012819A2
Authority
BR
Brazil
Prior art keywords
patient
kit
myelofibrosis
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112022012819A
Other languages
English (en)
Inventor
J Giles Francis
Mazar Andrew
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of BR112022012819A2 publication Critical patent/BR112022012819A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA TRATAR MIELOFIBROSE EM UM PACIENTE E KIT. A presente invenção fornece métodos de tratamento de mielofibrose em um paciente pela administração ao paciente de uma quantidade terapeuticamente eficaz de um inibidor de GSK-3ß tal como 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5H-[ 1,3]dioxol[4,5-f]indol-7-il)pirrol-2,5-diona, ou um sal farmaceuticamente aceitável do mesmo, opcionalmente em combinação com uma quantidade terapeuticamente eficaz de um inibidor de JAK, tal como ruxolitinib, ou um seu sal farmaceuticamente aceitável.
BR112022012819A 2019-12-26 2020-12-23 Método para tratar mielofibrose em um paciente e kit BR112022012819A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
BR112022012819A2 true BR112022012819A2 (pt) 2022-09-06

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012819A BR112022012819A2 (pt) 2019-12-26 2020-12-23 Método para tratar mielofibrose em um paciente e kit

Country Status (11)

Country Link
US (1) US20230062278A1 (pt)
EP (1) EP4081213A1 (pt)
JP (1) JP2023508491A (pt)
KR (1) KR20230005808A (pt)
CN (1) CN115697323A (pt)
AU (1) AU2020415440A1 (pt)
BR (1) BR112022012819A2 (pt)
CA (1) CA3166251A1 (pt)
IL (1) IL294369A (pt)
MX (1) MX2022008046A (pt)
WO (1) WO2021133866A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
KR20210037012A (ko) * 2012-11-15 2021-04-05 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3074016A2 (en) * 2013-11-26 2016-10-05 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
BR112020023422A2 (pt) * 2018-05-17 2021-02-17 Actuate Therapeutics, Inc. método para tratar fibrose pulmonar idiopática (ipf) em um indivíduo mamífero, método para inibir a proliferação ou diferenciação de miofibroblastos de pulmão em fibroblastos (fl) de pulmão fibrótico ou para redução da proliferação de fibroblastos fl, composição farmacêutica, uso da composição farmacêutica e uso de uma composição farmacêutica
MX2020013163A (es) * 2018-06-05 2021-02-18 Actuate Therapeutics Inc Metodos para tratar trastornos linfoproliferativos malignos.

Also Published As

Publication number Publication date
KR20230005808A (ko) 2023-01-10
WO2021133866A1 (en) 2021-07-01
CA3166251A1 (en) 2021-07-01
US20230062278A1 (en) 2023-03-02
AU2020415440A1 (en) 2022-08-04
EP4081213A1 (en) 2022-11-02
JP2023508491A (ja) 2023-03-02
MX2022008046A (es) 2022-11-14
IL294369A (en) 2022-08-01
CN115697323A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2018009539A (es) Uso de comunidades microbianas para la salud humana y animal.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MX2021012391A (es) Composiciones y metodos para mejorar la salud de la piel y para el tratamiento y la prevencion de enfermedades, trastornos y afecciones asociados con microbios patogenos.
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
MX2013008729A (es) Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
MX2022000845A (es) Compuestos inhibidores.
ZA202304965B (en) Combination therapy for treating cancer
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2020010606A (es) Compuestos de pladienolida y su uso.
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
BR112022012819A2 (pt) Método para tratar mielofibrose em um paciente e kit
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MY189221A (en) Medicament for treatment of diabetic foot infections
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]